VIDAZA (Celgene Corporation)
Welcome to the PulseAid listing for the VIDAZA drug offered from Celgene Corporation. This Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Celgene Corporation |
NON-PROPRIETARY NAME: | azacitidine |
SUBSTANCE NAME: | AZACITIDINE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |
ROUTE: | INTRAVENOUS; SUBCUTANEOUS |
DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2004-07-05 |
END MARKETING DATE: | 0000-00-00 |
VIDAZA HUMAN PRESCRIPTION DRUG Details:
Item Description | VIDAZA from Celgene Corporation |
LABELER NAME: | Celgene Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 100(mg/1) |
START MARKETING DATE: | 2004-07-05 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 59572-102_2ee396fc-bd5b-444a-8f18-0760c6e7c4cf |
PRODUCT NDC: | 59572-102 |
APPLICATION NUMBER: | NDA050794 |
Other AZACITIDINE Pharmaceutical Manufacturers / Labelers: